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Rapid pathway prototyping and engineering using
in vitro and in vivo synthetic genome SCRaMbLE-in
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Exogenous pathway optimization and chassis engineering are two crucial methods for
heterologous pathway expression. The two methods are normally carried out step-wise and
in a trial-and-error manner. Here we report a recombinase-based combinatorial method
(termed “SCRaMbLE-in”) to tackle both challenges simultaneously. SCRaMbLE-in includes an
in vitro recombinase toolkit to rapidly prototype and diversify gene expression at the pathway
level and an in vivo genome reshufﬂing system to integrate assembled pathways into the
synthetic yeast genome while combinatorially causing massive genome rearrangements in
the host chassis. A set of loxP mutant pairs was identiﬁed to maximize the efﬁciency of the
in vitro diversiﬁcation. Exemplar pathways of β-carotene and violacein were successfully
assembled, diversiﬁed, and integrated using this SCRaMbLE-in method. High-throughput
sequencing was performed on selected engineered strains to reveal the resulting genotype-
to-phenotype relationships. The SCRaMbLE-in method proves to be a rapid, efﬁcient, and
universal method to fast track the cycle of engineering biology.
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One of the exciting recent developments in industrialbiotechnology is the synergy between synthetic biologyand metabolic engineering to produce fuels, novel
medicine and high-value chemicals, nutrition supplements,
anti-tumor molecules, and antibiotics1–3. In traditional metabolic
engineering, metabolic analysis, substrate optimization, and direct
genetic modiﬁcation were often trial-and-error exercises4, while
synthetic biology provides an opportunity to engineer biology in a
more standardized and rational fashion. With the continually
dropping cost of DNA synthesis and innovation of DNA
assembly methods5,6, a wide range of metabolic pathways have
been constructed and transformed to heterologous hosts7–9.
However, introducing a new pathway into a host organism is
likely to be accompanied with low production of desired
compound molecules due to substrate or co-factor limitations;
compromised growth of the host; or even toxicity to the
host10. A number of methods have been developed to diversify
the expression of heterologous pathways, such as the combina-
torial assembly of gene expression units, genes expression reg-
ulation using CRISPR, protein engineering and pathway
compartmentalization3,11–16. Despite all the progress that has
been made, pathway optimization and chassis engineering
remains time- and resource-intensive3,4. This is best illustrated by
the heroic effort to engineer yeast to produce artemisinin, which
required roughly 100 post-doc years8.
Site-speciﬁc recombinases are a family of DNA modifying
enzymes that can recognize and drive recombination between two
speciﬁc DNA sites to generate deletion, inversion, or integration
of DNA fragments between the target sites. The well-studied Cre
recombinase recognizes a 34 bp loxP site and drives recombina-
tion without any co-factors17. The direction of the recombination
site determines the type of recombination activity. Site-speciﬁc
recombinase Cre has been widely applied to gene editing and
genome engineering in vivo18,19 and the loxP site has also been
engineered for better integration efﬁciency and cassette exchange
purposes17,20–22. Not only can Cre recombinase drive DNA
recombination in vivo, it has also been puriﬁed and shown to
function in vitro23. A number of Cre orthologues, including Dre
and VCre, have recently been identiﬁed by genome mining and
demonstrated to have in vivo function23–25. Additionally, Chuang
et al.26 carried out an extensive mutant library screening, and
identiﬁed novel rox sites, which can efﬁciently recombine with
themselves in vivo but have minimal to no reactivity with wild-
type (WT) rox sites26.
Besides the expression level of the target genes, the choice of
host and the genetic background of the host is of vital importance
for heterologous pathway production27,28. Repressing competing
pathways and knocking out non-essential genes interacting with
the target pathway can re-direct the precursor transformation
ﬂuxes in the metabolic maps or remove toxicity of side products
to potentially achieve higher target production. However, refac-
toring the host genome could potentially impact ﬁtness of the cell,
and genome-wide chassis optimization is still a daunting endea-
vor. Traditional mutagenesis and genome-editing technologies
such as TALEN- and CRISPR/Cas9-based methods typically
introduce a limited number of site-speciﬁc mutation(s)29–31, but
not large-scale genome-wide rearrangements such as inter- and
intra-chromosomal translocations. In the synthetic yeast genome
Sc2.0 project (www.syntheticyeast.org), the SCRaMbLE system
(Synthetic Chromosome Rearrangement and Modiﬁcation by
loxP-mediated Evolution) was designed to introduce genome-
wide loxPsym sites and can generate a massive number of
genome permutations upon induction32,33. SCRaMbLEing the
synthetic yeast strains under selective conditions allows
efﬁcient directed evolution of desired phenotypes. With con-
tinuing successful synthesis and construction of these synthetic
chromosomes18,34–37, the synthetic yeast is becoming a very
attractive platform for metabolic engineering.
In this study, we developed a recombinase-based toolkit
“SCRaMbLE-in” to enable rapid metabolic engineering through
pathway prototyping and chassis optimization in yeast.
SCRaMbLE-in is composed of two steps, which can be used either
independently or combined. The ﬁrst step is to use puriﬁed
recombinases in vitro to integrate regulatory elements into tar-
geted pathways to diversify gene expression. The second step is to
randomly integrate the assembled pathway into the synthetic
yeast chromosomes through the SCRaMbLE-in process, which
also causes large-scale genome rearrangements. The violacein and
β-carotene pathway are used to demonstrate the effectiveness and
simplicity of the SCRaMbLE-in method. We also demonstrate
that the yield of both pathways can be further optimized with
continuous genome SCRaMbLEing.
Results
Design of the SCRaMbLE-in system. Gene expression diversi-
ﬁcation and strain optimization are at the core of metabolic
engineering. In order to achieve differentiated gene expression
and chassis engineering simultaneously, a two-step diversiﬁcation
method was designed (Fig. 1).
Firstly, an in vitro recombinase toolkit was designed to
integrate a range of regulatory elements into the pathways of
interest (Fig. 1a). In this step, regulatory elements such as
promoters are ﬂanked by the recombinase recognition sites in the
same orientation. A single recombinase recognition site is
engineered into the desired integration position of the
pre-assembled pathway. In the case of promoter integration,
the target site should be immediately upstream to the key
enzyme-coding sequence. Three recombinases, Cre, VCre, and
Dre, were puriﬁed for use in the integration step. The regulatory
elements, selected recombinase and target pathway DNA are
mixed in a single reaction, and the recombinase will integrate the
regulatory elements into the target recombination site to generate
a combinatorially assembled pathway library. The library can
then be transformed directly into the yeast for downstream
screening and analysis.
Secondly, a SCRaMbLE-in vector has been designed to
integrate the target pathway into the synthetic genome through
SCRaMbLE (Fig. 1b). In this vector, the target pathway DNA is
ﬂanked by the symmetric loxPsym sites. This will allow the Cre
recombinase to integrate the target pathway into any loxPsym
sites in the synthetic genome. Additionally, the active Cre will
also mediate the rearrangement of the synthetic genome,
through deletion, inversion, and duplication events, which act
to diversify the host genetic background. With proper selection,
the host canbe rapidly optimized to better accommodate the
heterologous pathway.
Quantiﬁcation of the in vitro activity of recombinases. To
construct the in vitro recombinase toolkit, we ﬁrst puriﬁed and
quantiﬁed the activity of three tyrosine recombinases, Cre, Dre,
and VCre. The proteins were tagged with C-terminal hexa-his-
tidine tag and puriﬁed by nickel afﬁnity chromatography, and
subsequently assessed by SDS-PAGE and veriﬁed by MALDI
peptide mass ﬁngerprinting (Supplementary Fig.1a, b). The test
plasmids were designed as shown in Supplementary Fig. 1c.
The recombinase will excise the DNA fragment ﬂanked by its
recognition sites (Table 1), producing two circular DNA
molecules that can be distinguished after ScaI digestion.
Therefore, the activity of the recombinase can be monitored by
measuring the successful production of the resulting recombined
plasmids. We tested the activity of Cre and VCre against both of
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their recombination sites and found that the two recombinases
are orthogonal to each other, i.e., Cre only recombines at the loxP
sites and VCre only acts on the VloxP sites (Supplementary
Fig. 1e). Furthermore, Dre and VCre are also orthogonal to each
other, while Dre has slight cross-activity on loxP sites and is thus
not strictly orthogonal to Cre in vitro (Supplementary Fig. 1e).
To quantify the in vitro recombination efﬁciency, two
strategies were designed to measure the excision and integration
rates respectively (Supplementary Fig. 1d). The excision rate was
assayed by monitoring the loss of an RFP gene ﬂanked by a pair
of recombinase targeting sites in a reporter plasmid, and deﬁned
as the percentage of white colonies on ampicillin selection
medium after transforming the reaction mixture into Escherichia
coli. To measure the integration rate, an accepting vector was
constructed, which contains a kanamycin-resistance gene and a
single recombination site. In addition, the above-mentioned
reporter plasmid was modiﬁed to include a ccdB gene38. Upon
recombinase treatment, if the excised RFP gene is inserted into
the accepting vector, a red colony will be produced on
kanamycin-containing medium. The presence of ccdB gene
prevents the formation of red colonies due to co-transformation
of the two original plasmids. The integration rate was deﬁned as
the percentage of red colonies after kanamycin selection. As
depicted in Supplementary Fig. 1f, the excision rate of Cre-loxP
system is over 40%, while VCre-Vlox and Dre-rox systems are
slightly lower (about 30%). The relative integration rate is around
0.6% for Cre-loxP and Dre-rox and around 0.3% for VCre-Vlox
(Supplementary Fig. 1g). These results indicate that all three
recombinases are active in vitro with slightly variable excision and
integration rates.
One potential explanation for the low integration rate might be
the re-excision of RFP cassette from the accepting vector.
Therefore, using Cre-loxP as an example, we aimed to increase
the rate by introducing mutations into the loxP sites at left or
right palindromic arm, termed as left element (LE) and right
element (RE)17. The loxP site containing both LE and RE could
greatly reduce its afﬁnity for the Cre recombinase and conse-
quently preventing the integrated DNA from being excised
(Fig. 2a). Five loxP mutants, lox71, lox66, loxJT15, loxJT510, and
loxJTZ17, which were reported to increase the integration rate in
ES cells and E. coli were tested39,40. Among them, loxJT15 and
loxJT510 only have LE mutation, and loxJTZ17 only has RE
mutation. Therefore, we constructed the RE mutation sites of
loxJT15 and loxJT510 and the LE mutation site of loxJTZ17
(Table 2). The in vitro excision assay was carried out both
between the same loxP mutant sites and between the LE:RE
hybrid site and WT site. The result of quantiﬁcation is
summarized in Fig. 2b. In general, we observed that the excision
rates of cognate recombination site pairs were higher than that of
LE:RE–WT pairs, which suggests the LE/RE strategy is also
applicable in vitro (Fig. 2c). Interestingly, loxJTZ17-containing
hybrid sites showed the lowest excision rate when recombined
with the loxP site, while loxJTZ17 yielded high recombination
rate with itself, making it the best candidate for integration
improvement. After examining the integration rate, we found that
the hybrid site of loxJTZ17 and loxJT15 performs the best,
leading to about a three-fold increase relative to the WT site
(Fig. 2d). Hence the loxJT15 and loxJTZ17 pair was chosen for
next-step application of promoter integration.
Considering the palindromic structure of recombination
sites, their hairpin structure could potentially affect transcrip-
tional or translational efﬁciency of the downstream target
gene after element integration41. We examined this effect
by using a GFP reporter (Supplementary Fig. 2). We integrated
Table 1 Recombinase and target sites
Name Target site Length Site sequence
Cre loxP 34 bp ATAACTTCGTATAGCATACATTATACGAAGTTAT
Dre rox 32 bp TAACTTTAAATAATTGGCATTATTTAAAGTTA
VCre Vlox 34 bp TCAATTTCCGAGAATGACAGTTCTCAGAAATTGA
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Fig. 1 Schematic overview of the SCRaMbLE-in toolkit for metabolic engineering. Once designed, the synthetic pathway of interest will be rapidly
prototyped in vitro. The pathway is pre-assembled in such a way that all genes are assembled with respective regulatory elements, except that one key
gene is left “promoter-less”, having a recombination site upstream. Three recombination systems, Cre-loxP, VCre-Vlox, and Dre-rox, were developed to
integrate a range of promoters upstream to the key gene in the pathway. The assembled library is transformed into yeast and potentially productive
pathways are selected and integrated in vivo in the next step. The selected productive pathways are ﬂanked with a pair of loxPsym sites and can
subsequently be integrated into the synthetic chromosomes through SCRaMbLE, and simultaneously the synthetic yeast chassis undergoes whole-genome
rearrangement to result in strain optimization. The successful integrated strains will be proﬁled with mass spectrometry analysis and next-generation
sequencing
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three recombination sites, loxP, loxJT15:JTZ17, and Vlox,
between three promoters of different strengths and the GFP
gene. We found that the recombination sites have a similar
impact on gene expression regardless of the promoter strength
(Supplementary Fig. 2). Of the three recombination sites, the
double-mutant site loxJT15:JTZ17 has the minimum impact,
which could be due to its asymmetric structure. Therefore,
the LE/RE strategy not only improves integration efﬁciency
but also helps to minimize the transcriptional effect of the
recombination site on the target gene of interest.
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Fig. 2 Integration rate improvement by LE/RE strategy. a LE/RE strategy was used to improve the integration efﬁciency. The functional domains of a
recombination site are divided as a spacer region and two palindromic regions. The recombination between LE and RE mutation site generates a LE:RE
double-mutant site and a wild-type loxP site. For in vitro application, a genetic Element of Interest (EoI) ﬂanked by two LE sites is ﬁrst excised out, and then
integrates into an RE site, ﬁnally being ﬂanked by a LE/RE site and a loxP site. b Excision rate quantiﬁcation of palindromic mutant site pairs (LE–LE or
RE–RE) and double-mutant site and loxP site (LE:RE-loxP). LE includes lox71, loxJT15, loxJT510, loxJTZ17LE; RE includes lox66, loxJT15RE, loxJT510 RE,
loxJTZ17. Error bar represents the standard deviation, n= 3. c Excision rate comparison between same pair recombination group and LE:RE–WT pair
recombination group. Center value represents the mean of the excision rates. t test was performed for difference evaluation between the two groups. d
Integration rate quantiﬁcation of selected LE- and RE-mutant sites. The integration rate between loxJT15 and loxJTZ17 is three-fold of that between loxP
site. Error bar represents the standard deviation and P value was generated by t test, n= 3. LE, left element with mutation in left palindromic region, RE,
right element with mutation in right palindromic region
Table 2 Palindromic arm mutants of loxP
Lox mutant Mutation element Sequence
loxP WT ATAACTTCGTATAGCATACATTATACGAAGTTAT
lox71 LE taccgTTCGTATAGCATACATTATACGAAGTTAT
lox66 RE ATAACTTCGTATAGCATACATTATACGAAcggta
loxJT15 LE AattaTTCGTATAGCATACATTATACGAAGTTAT
loxJT15 right RE ATAACTTCGTATAGCATACATTATACGAAtaatT
loxJT510 LE taAcgTTCGTATAGCATACATTATACGAAGTTAT
loxJT510 right RE ATAACTTCGTATAGCATACATTATACGAAcgTta
loxJTZ17 left LE ATAAaTTgcTATAGCATACATTATACGAAGTTAT
loxJTZ17 RE ATAACTTCGTATAGCATACATTATAgcAAtTTAT
Uppercase indicates wild-type bases; lower case indicates mutation bases. Underline indicates spacer region
LE left element, RE right element, WT wild type
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Pathway prototyping with the in vitro recombinase toolkit. The
in vitro recombinase toolkit consists of a regulatory element
loader plasmid and an acceptor plasmid (Supplementary Fig. 3a).
When recombinase is present, the regulatory element will be
excised from the loader plasmid and then integrated into the
acceptor plasmid to activate and diversify the target gene
expression. We have previously reported the construction and
characterization of a standardized yeast parts library called
YeastFab10. To match our in vitro recombinase toolkit with the
YeastFab library, several standardizations of the tool plasmids
were made. An RFP expressing unit ﬂanked by two YeastFab
matched type IIs restriction sites was included in the loader to
facilitate the loading of standardized elements from YeastFab by
Golden Gate assembly and an URA3 marker was used for
selection in yeast (Supplementary Fig. 3b). The acceptor plasmid
pWL121 has a similar structure and two homologous arms are
included for genome integration at HO locus with HIS3 selection
(Supplementary Fig. 3c). We randomly chose 25 promoters in the
YeastFab part library with strength varying from 2- to 54-fold
relative to that of the pCYC1 promoter as the regulatory elements
in this study (Supplementary Fig. 3d, Supplementary Table 1).
Based on the integration characterization and GFP expression
results, Cre-loxJT15:JTZ17 and VCre-Vlox were chosen for
pathway diversiﬁcation. Two exemplar pathways, the β-carotene
and violacein synthesis pathways, were selected as demonstration.
We selected CrtI, the critical gene to transform the colorless
phytoene to lycopene in β-carotene synthesis, and VioA, the key
starting gene transforming L-tryptophan to violacein, as target
genes to test promoter integration42 (Fig. 3a, c). With the in vitro
recombinase reaction, a combinatorial library of β-carotene
synthesis pathway with 25 YeastFab promoters driving the CrtI
gene was generated (Supplementary Fig. 4). The library was then
transformed into yeast strain BY4741 and selected on SC-His-Ura
plates, which produced yeast colonies of different intensities of
orange/yellow colors as well as differing colony sizes, indicating
varying yields of carotenoid (Supplementary Fig. 5). The inte-
gration of the promoter was conﬁrmed by Sanger sequencing, and
the ﬁtness and chemical analysis of several selected variants were
further compared (Fig. 3b, d). The yield of carotenoid lycopene
and β-carotene were quantiﬁed by liquid chromatography-mass
spectrometry (LC-MS) and the activity of the integrated pro-
moters was also compared. The result shows that the carotenoid
production is not proportional to the activity of the promoters.
The medium promoter pACT1 integrated strain have a similar
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Fig. 3 In vitro pathway prototying of β-carotene and violacein pathways. a Illustration of gene function in β-carotene synthesis pathway. CrtI was chosen as
the target gene for integration regulation in β-carotene pathway. CrtI encodes the desaturase that converts the colorless phytoene to the yellow
neurosporene ﬁrst and then to the red lycopene through four desaturation reactions. Since it is a key enzyme in catalyzing the colorless intermediates to
colored molecules, the extent of yellow, red, or orange can indicate the transformation efﬁciency and visibly display diversiﬁcation of the pathway with
various expression of CrtI. b Promoter integration conﬁrmation and LC-MS quantiﬁcation of carotenoids in β-carotene pathway. VCre-Vlox system was
used for CrtI regulation. Seven promoter-integrated strains were quantiﬁed. Error bar represents the standard deviation, n= 3. LC-MS, liquid
chromatography and mass spectrometry. c Illustration of gene function in violacein synthesis pathway. VioA was chosen as the target gene for integration
regulation in violacein pathway. VioA encodes the ﬂavoenzyme L-tryptophan oxidase that catalyses the incorporation of two molecules of substrate L-
tryptophan into indole-3-pyruvic acid imine. It catalyzes the initial step in the violacein synthesis and is important for transforming enough tryptophan
substrates for following steps towards full synthesis of the pathway. d Promoter integration conﬁrmation and HPLC quantiﬁcation of violacein. Both VCre-
Vlox system and Cre-loxJT15-loxJTZ17 system were used for VioA regulation. Six promoter-integrated strains were quantiﬁed. Error bar represents the
standard deviation, n= 3. HPLC, high performance liquid chromatography
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carotenoid yield with pTDH3, while pRPL22B integrated strains
have the lowest β-carotene yield even though it is not the weakest
promoter (Fig. 3b). Moreover, the result shows different ratios of
β-carotene to lycopene are generated (Fig. 3b). Besides difference
in yield, the ﬁtness of the integrated strains also varies (Supple-
mentary Fig. 6a). For example, the low yield strain with pYPT1
and pRPL22B have longer doubling time and lower saturation cell
densities while the high yield strain with pTDH3, pHSP12, and
pACT1 have shorter doubling times and higher saturation point.
Although the production levels in strains with pSTE2 or pHXK1
were quite different, the ﬁtness for the two strains is similar. Such
ﬁtness differences could be the result of metabolic burden from
the intermediates of β-carotene pathway and the ﬂux could be
affected by promoter choice.
In contrast, for the violacein pathway, the production of
violacein and the activity of the integrated promoters were in
proportion with only one exception of pPNC1 (Fig. 3d and
Supplementary Fig. 6b). The ﬁtness of the promoter-integrated
strains of violacein pathway is similar to each other with the only
slower one integrated with pSCW4.
Our results suggest promoter strength does not always
correlate with the ﬁnal pathway production, and the selection
will also impact the ﬁtness of the host due to cellular burdens.
The in vitro SCRaMbLE-in toolkit allows rapid prototyping of
synthetic pathways, and allows the identiﬁcation of combinations
of genetic parts, which can work well together to lead to a
productive pathway. The selected pathways can then be stably
integrated into the genome in the next step.
One-step pathway integration and strain evolution. Besides
speciﬁc gene regulation and engineering, the genome context can
be optimized for the pathway in a synthetic yeast background
through our in vivo SCRaMbLE-in method. We chose synthetic
chromosome II, which contains 410 open-reading frames and
267 loxPsym sites, as the target chromosome for pathway inte-
gration36. When SCRaMbLE is activated, the pathway can be
integrated randomly into the synthetic chromosome with
simultaneously random gene deletion, inversion, and duplication
of the chromosome. Similar to the in vitro element loader plasmid
pWL121, we used a same pair of BsaI sites to ﬂank the RFP
cassette for the construction of pathway SCRaMbLE-in loading
plasmid pWL032 by Golden Gate assembly and a LEU2 auxo-
trophic marker for selection (Fig. 4a). The assembly compatibility
enables convenient loading of the library pathways generated
from in vitro promoter integration for subsequent in vivo
genome integration and chassis diversiﬁcation. When the
recombinase is expressed in the synII background, the pathway is
ﬁrst excised out from the URA3-marked plasmid and then ran-
domly integrated into the synthetic chromosome. To ensure we
only select true integrated strains, 5-FOA counter selection was
applied (Fig. 4a and Supplementary Fig. 7a). Genetic composi-
tions of the two pathways are summarized in Supplementary
Table 2.
The in vitro result shows that the control strain LWy137 (synII
background) with the HO-integrated violacein pathway has a
yield of around 1 mg/L, while in the SCRaMbLE-in strains
LWy152 and LWy238 the yields are around 5 mg/L, almost ﬁve-
fold more than that of the control strain. The highest yield was
identiﬁed in the SCRaMbLE-in strain LWy239, which lead to an
almost ten-fold increase than that of the control strain (Fig. 4b).
For the β-carotene pathway, the total yield of β-carotene for the
HO-integrated strain LWy212 (BY4741 background) is around
250 μg/L. The total yield of β-carotene of the two SCRaMbLE-in
strains LWy215 and LWy253 are similar, but LWy215 is slightly
lower than the control, while LWy253 is higher than the control.
The total yield of β-carotene for LWy252 is around 500 μg/L,
which is twice that of the control strain (Fig. 4c).
Next, we tried to continuously evolve the strains with multiple
rounds of SCRaMbLE. Given that the chemical production of the
violacein pathway can be roughly estimated from the color of
the colony, synII strains with the violacein synthesis pathway
integrated were chosen for a continuous SCRaMbLE experiment.
Three SCRaMbLE-in strains veriﬁed by next-generation sequen-
cing, LWy152, LWy238, and LWy239, were re-transformed with
a fresh pSCW11-Cre-EBD plasmid43 for continuous SCRaMbLE.
After a 24 h induction, the cells were plated onto SC-Leu plates
to isolate single colonies. In all three cases of re-SCRaMbLE,
we observed clones with darker and lighter colors compared
with the original strains, indicating increased and decreased
violacein production, respectively (Supplementary Fig. 7b). The
colonies were then standardized to OD600= 1.0 at log phase and
spotted to SC-Leu to compare the color difference more clearly
(Fig. 4d).
After an initial screen by color variation, the composition of
violacein and its ratio with the intermediate proviolacein was
quantiﬁed in the SCRaMbLEd strains. The high-performance
liquid chromatography (HPLC) result shows that the peak
areas of violacein and proviolacein were diversiﬁed among
the SCRaMbLEd strains (Supplementary Fig. 8a). LWy256
(LWy152+) has the highest violacein yield of 16.8 mg/L, with
more than three-fold that of LWy152 and nearly 17-fold that of
the control strain. The yield of LWy258 (LWy238+) is 1.5-fold
that of the LWy238 strain. The yield of LWy260 (LWy239+) is
similar to that of LWy239. For LWy257 (LWy152−) and LWy259
(LWy238−) with lighter color, their violacein production was
reduced to around 0.5 mg/L, which is about 1/10 of the original
strains. The yield of violacein in LWy261 (LWy239−) is slightly
reduced to 3.5 mg/L. The ratio of violacein to proviolacein in
LWy152, LWy257, and LWy259 are similar at around 0.7. In
LWy238, LWy258, LWy239, and LWy260, the ratio varies from
1.4 to 1.9. Among these strains, LWy256 has the highest violacein
to proviolacein ratio at 3.0 (Supplementary Fig. 8).
Deep sequencing deconvolution of SCRaMbLE-in strains. By
analyzing the PCRtags (Supplementary Fig. 9), we identiﬁed that
both the LWy257 and LWy259 strains had lost the same pair of
PCRTags in the gene YBR044C. To investigate whether the
lower violacein yields in these two strains was due to YBR044C
deletion, a gene complementation experiment was performed
(Supplementary Fig. 10). The YBR044C transcription unit was
cloned into a pRS413 vector and transformed into both strains
and their parental strains, respectively. The result shows that with
the addition of an extra copy of YBR044C, both LWy257
and LWy259 recovered to give a color intensity similar to the
original LWy152 and LWy238, indicating that the loss of
YBR044C function contributes to the reduced violacein yield in
these strains. The YBR044C gene encodes a mitochondrial
membrane protein, a putative chaperone involved in the assembly
of the succinate dehydrogenase (SDH) complex44. The deletion of
YBR044C did not affect the viability of the cell but could
potentially interrupt the function of SDH and further affect the
tricarboxylic acid cycle and the mitochondrial respiration chain
in Saccharomyces cerevisiae. A working hypothesis could be that
the violacein synthesis process is NADPH-dependent, and the
deletion of YBR044C affects the reducing power of the cell, and
indirectly affecting the normal NADPH level, which impedes the
production of violacein.
Next-generation sequencing was performed on the
SCRaMbLE-in strains. The sequencing results indicate that
the entire violacein pathway has been successfully integrated into
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the synthetic chromosome II (GenBank accession: CP013608.1)
at the loxPsym sites at different locations (Fig. 5a and
Supplementary Fig. 11). Besides the integrated pathway, many
other genome rearrangements in these strains were observed
(Fig. 5a and Supplementary Fig. 11), including 26 deletions, 36
inversions, and 32 duplications (Supplementary Data 1). Parti-
cularly, large duplications (over 500 kb) were observed in
LWy238 and its derived strains LWy259 and LWy258. Whole-
chromosome duplication was identiﬁed in LWy239 and its
derived strains LWy260 and LWy261. One possible explanation
that the SCRaMbLE process somehow interferes with the
synthetic chromosome segregation process, resulting in one
daughter cell with aneuploidy. The largest rearrangement was
identiﬁed in LWy256 with a length of 1544.17 kb (Fig. 5a and
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Supplementary Fig. 11), which resulted from a fusion event of two
SCRaMbLEd synII chromosomes (Supplementary Fig. 12a). This
fusion event leads to the presence of two centromeres in this
chromosome, with one of which inverted (Supplementary
Fig. 12b). This is supported by the sequencing, PCR and PFGE
results (Supplementary Fig.12c, d). The segregation process of
this chromosome during cell cycle will be worth studying further,
and presumably, one of the centromeres is defective. Considering
the complex genotype variations in these strains, it is still difﬁcult
to isolate the key variation, or comprehensive effects from
numerous variations. Nonetheless, the SCRaMbLE-in and con-
tinuous SCRaMbLE processes could provide a platform to
generate a rich source of genome rearrangements, which can be
further studied with computational and systems biology methods
in the future.
Orthogonal-inducible SCRaMbLE system for future applica-
tions. For further extended applications of recombinases in the
synthetic yeast, two controllable orthogonal recombinase
expression systems were designed and veriﬁed (Fig. 6). The
ligand-binding domains (LBDs), including progesterone-binding
domain (PBD) and β-estradiol-binding domain (EBD), which
have been shown to be able to mediate the translocation of fused
protein from the cytoplasm into the nucleus upon ligand bind-
ing43,45, were used to control the activity of two recombinase
orthologues, Cre and Dre. The TDH3 promoter was used to drive
the expression of Cre and Dre, with and without the LBDs in a
pRS415-based yeast centromeric plasmid, and a reporter plasmid
was constructed in a pRS413-based plasmid where a URA3
expression cassette is ﬂanked by a pair of corresponding recom-
bination sites (Fig. 6a). Both the recombinase expression plasmid
and the reporter plasmid were transformed and selected into
yeast strain BY4741. The orthogonality of Cre and Dre without
LBD fusion was ﬁrst veriﬁed by directly spotting on selective
media to assay the recombinase activities (Fig. 6b). Yeast cells
with the reporter plasmid rox-URA3-rox did not survive with Dre
expression and cells with the reporter plasmid loxP-URA3-loxP
could not survive with Cre expression on SC-His-Leu-Ura plate,
proving the activities of the two recombination systems in vivo.
The Cre recombinase does not recognize the rox-URA3-rox, nor
does the Dre recombinase recombines out the loxP-URA3-loxP,
showing the orthogonality of the two recombinases. We then
fused Dre with EBD and Cre with PBD, in order to make the
recombinase activities inducible. We demonstrated recombinase
activity can be induced by 48 h induction of either 1 μM β-
estradiol for DreEBD or 1 μM RU486 for CrePBD. Without the
corresponding ligand induction, the recombinase activities are
turned off (Fig. 6c). Two rounds of β-estradiol induction were
performed as well to achieve a maximal function of DreEBD
(Supplementary Fig. 13). In future, the two orthogonal inducible
recombination systems can be applied to achieve modular
SCRaMbLE/SCRaMbLE-in in either speciﬁc regions of the syn-
thetic genome, or even whole-novel-designed synthetic chromo-
somes, such that more than one pathway can be simultaneously
integrated into different genomic loci. The orthogonal modular
SCRaMbLE could also facilitate the generation of non-lethal
genome rearrangements and evolve the chassis more efﬁciently
for metabolic engineering and other diverse purposes in the Sc2.0
project.
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Discussion
The synergy between synthetic biology and metabolic engineering
has attracted more and more attention, along with its successful
application in biological materials production. In the past dec-
ades, synthetic biology has been widely used in the design,
modiﬁcation and assembly of genetic elements, signiﬁcantly
speeding up the metabolic engineering process, and succeeding in
the production of several important metabolites. Recently, great
progress has been made in the yeast synthetic genome project—
Sc2.0. Six synthetic chromosomes have been successfully syn-
thesized and all are functional in vivo. The synthesized yeast
genome offers a unique platform to perform the rapid strain
engineering methods such as the SCRaMbLE-in methodologies
described in this paper. SCRaMbLEing the synthetic yeast
has been proved to be able to generate various genotypes and
phenotypes through Cre-mediated rearrangements utilizing the
implanted loxPsym sites. In this study, a rapid, efﬁcient, and
universal method called SCRaMbLE-in was designed and
demonstrated to be a new method to fast track the cycle of
engineering biology, presenting a new synergy area between
synthetic biology and metabolic engineering.
Combinatorial assembly has been instrumental in synthetic
biology for exploring a large design space. Broadly speaking, there
are two categories of combinatorial assembly methods: one is
based on complementary overhang sequences5,12,46, and the other
one is using homologous bridging sequences11,47.
The SCRaMbLE-in utilizes site-speciﬁc recombinases to achieve
efﬁcient combinatorial library construction, and provides an
alternative method to diversify metabolic pathways. It is
sequence-independent and can be applied to virtually any parts
and pathways. The SCRaMbLE-in method also allows
random integration of the pathway into a genomic locus, and at
the same time optimize the host Sc2.0 strain, which are not
possible with any existing combinatorial methods.
In the SCRaMbLE-in method, the gene expression diversiﬁ-
cation, pathway integration, and chassis evolution processes were
tackled conveniently through our in vitro recombinase toolkit and
in vivo synthetic genome SCRaMbLE-in system. The SCRaMbLE-
in method not only allows researchers to integrate pathways into
the synthetic yeast genome, but also allows the genetic back-
ground to be evolved and selected. In addition to the genetic
background, the location of integration could affect the tran-
scription efﬁciency depending on chromatin structure and the
degree of heterochromatinization48–51. Moreover, the scattered
cis-acting elements and other not fully characterized untranslated
regions can also make a difference to pathway expression52.
Though some genomic loci have been studied51,53, the
majority of the genome remains uncharacterized. The combina-
torial nature of the SCRaMbLE-in method allows researchers
to explore a large, diversiﬁed, genetic space for the optimal
design(s). Additionally, the genome-integration feature allows the
stable presence of a pathway without generating extra burden of
plasmid maintenance in the host. When the heterologous path-
way imposes cellular burden to the host, SCRaMbLE provides a
unique opportunity for the host to evolve and to adapt to these
challenges.
No single strain can serve as a super host for multiple diverse
products. Even when a strain is optimized for the production of
one class of compound, this rarely translates to enhanced pro-
duction from different pathways, and so for each target, a lengthy
and costly trial-and-error process of strain engineering is required
to optimize production. The SCRaMbLE-in method we report
here will explore the synthetic yeast, S. cerevisiae 2.0 (Sc2.0), as a
generic platform for heterologous production of multiple valuable
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natural products. SCRaMbLE induces genome-wide sequence
duplication, deletion, inversion, and translocation, but does not
introduce point mutations. Such that it is possible to couple
SCRaMbLE with traditional random mutagenesis methods, and
recently developed high-throughput genome-wide site-directed
mutagenesis methods such as MAGE and RAGE54,55.
In our method, pathway SCRaMbLE-in and chassis evolution
are achieved in the same step and continuous SCRaMbLE could
be applied to further evolve the strains. This makes it particularly
attractive for long-term directed evolution experiments using
either batch transfer or chemostats. The pathway SCRaMbLE-in
vector can serve as a generic tool to integrate virtually any
pathway of interest into the synthetic yeast platform. With the
merging of multiple synthetic chromosomes and the complete
synthesis of the whole yeast genome in near future, the
SCRaMbLE-in method will have more use cases to explore.
Methods
Protein expression. A single colony of E. coli BL21 (DE3), transformed with either
the Cre, Dre, or VCre protein expression plasmid, was transferred into 10 mL LB
media, supplemented with 100 mg/L kanamycin and incubated overnight at 37 °C
with shaking, 180 r.p.m. The overnight pre-culture was then inoculated into 1 L of
LB medium with 100 mg/L kanamycin and incubated at 37 °C with 180 r.p.m.
shaking. Recombinant protein production was induced when the cell concentration
reached 0.6 (OD600) by the addition of 1 mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) and the incubation temperature was reduced to 18 °
C and cells were incubated for 16 hours. Cells were pelleted by centrifugation at
4000×g for 20 min, 4 °C, and resuspended in 10-fold (volume per gram of cell
pellet) of PBS to wash cells.
Protein puriﬁcation. Cells were resuspended in 10 times (volume per gram of cell
pellet) of HisA buffer (50 mM Tris.HCl pH 8.0, 50 mM imidazole, 500 mM NaCl)
and lysed by sonication at 4 °C, with ten cycles of 15 s bursts of sonication at 10-μm
amplitude followed by 15 s of cooling. The lysate was clariﬁed by centrifugation at
35,000×g for 30 min and the supernatant was ﬁltered using a 0.45 μm syringe ﬁlter.
The ﬁltered supernatant was loaded onto a 5 mL HisTrap FF column equilibrated
with HisA buffer. Unbound sample was washed off with 10 column volumes of
HisA buffer and protein was eluted with a linear gradient of 0–70% HisB buffer (50
mM Tris.HCl, pH 8.0, 500 mM imidazole, 500 mM NaCl) over 20 column volumes.
Peak fractions were analyzed by 15% SDS-PAGE and fractions containing the
protein of interest were pooled. Puriﬁed Cre, Dre, and VCre recombinase proteins
were extensively dialyzed into reaction buffer (50 mM Tris-HCl pH 7.5, 33 mM
NaCl, 10 mM MgCl2) before use in further assays, or stored by transferring to
50 μL aliquots in thin-walled PCR tubes and ﬂash-cooled in liquid nitrogen before
storage at −80 °C. The concentration was adjusted to 10 μM for future use.
In vitro recombinase quantiﬁcation assay. For excision rate measurement,
250 ng DNA were mixed with 10 μM recombinase and 5 μL 10X recombination
buffer (NEB) in a 50 μL reaction. Keep at 37 °C for 16 h and deactivate recombinase
at 75 °C for 15 min. Transform 10 μL into E. coli competent cell and select on LB
plate with 100 µg/mL ampicillin. For integration rate measurement, 300 ng RFP-
AmpR-ccdB plasmid and 100 ng KanR plasmid was mixed with 10 μM recombinase
and 10 μL 10X recombination buffer in a 100 μL reaction. The reaction was kept at
37 °C for 16 h and the recombinase deactivated at 75 °C for 15 min. E. coli com-
petent cells were transformed with 10 µL reaction and selected on an LB+
Kanamycin plate. Biological triplicates were performed for rate calculation. Soft-
ware ImageJ was used to facilitate counting of red and white colonies.
Promoter library integration by in vitro recombination. Twenty-ﬁve promoters
from YeastFab library were mixed and assembled with Vlox or loxJTZ15 promoter
loading vector by BsmBI Golden Gate assembly. For promoter integration, the
recombination reaction was set up by adding 1.5 μg promoter plasmids mixture,
800 ng HO-Vlox-CrtI β-carotene circuit, or HO-loxJTZ15-VioA violacein circuit,
10 μL 10X recombination buffer, VCre, or Cre to ﬁnal concentration of 100 nM,
and ddH2O to 100 μL. The reaction was kept at 37 °C for 16 h. Frozen competent
yeast cells were transformed as follows: The plasmid with promoter-integrated
pathway circuit in the reaction was cleaned by PureLink® PCR puriﬁcation kit and
further linearized by BsmBI for homologous recombination at HO locus. The
reaction was then mixed with 260 μL 50% PEG 3350, 36 μL 1.0 M lithium acetate,
10 μL 10 mg/mL single-stranded carrier DNA and distilled water to a ﬁnal volume
of 360 μL and transformed into 100 μL BY4741 competent cells56.
Hormone induction of CrePBD and DreEBD. Yeast cells were ﬁrst transformed
with a functional test device and selected on SC-His plates, then with the
recombinase expressing device pTDH3-CrePBD or pTDH3-DreEBD and selected
on SC-His-Leu plates. The fresh double-transformed strain was cultured overnight
in non-hormone containing SC-His-Leu liquid medium. The overnight culture was
re-inoculated to OD600 of 0.1 in SC-His-Leu with 1 µM either β-estradiol (E2257,
Sigma-Aldrich) or RU486 (M8046, Sigma-Aldrich) for induction in 30 °C for 48 h.
After induction, the cells were adjusted to OD600 of 1.0, serial diluted and spotted
on SC-His-Leu and SC-His-Leu-Ura plates for comparison.
In vivo SCRaMbLE-in and variant screening. Yeast with synthetic chromosome
II, synII (YSy115), was ﬁrst transformed with pathway SCRaMbLE-in plasmids,
pWL045 and pWL046 for the β-carotene and violacein pathways, respectively, and
selected on SC-Leu plates. The strains were further transformed with pRS413-based
pSCW11-CreEBD or pTDH3-CreEBD, respectively, and selected on SC-His-Leu
plates. Fresh transformants were picked from the plate and cultured in SC-His-Leu
liquid media overnight at 30 °C on a roller drum with duplicates for each strain.
Cells were inoculated into 10 mL fresh SC-His-Leu liquid medium to OD600 of 0.1
with 1 μM estradiol. Cells were cultured for 12, 24, or 48 h at 30 °C. At each time
point, serial dilution and spotting were performed on SC-Leu and SC-Leu with 1
mg/mL 5-FOA plates for SCRaMbLE-in efﬁciency evaluation. For SCRaMbLE-in
variant selection, cells were washed and collected after 24 h induction and were
spread onto SC-Leu plates with 5-FOA and incubated at 30 °C for 3 days. Variants
were selected by color or size and further genotypic veriﬁcation was performed.
Violacein extraction and HPLC quantiﬁcation. The violacein-expressing yeast
strain was cultured in corresponding selection media for 5 days at 30 °C. Three
mililiters to 5 mL culture was transferred to a 15 mL Falcon tube, spun down at top
speed, and washed twice with deionized water. Samples were boiled with 1 mL
methanol at 90 °C for 10 min. The debris was spun down at 17,000×g for 30 min.
The supernatant was transferred to a HPLC glass vial through syringe with needle
and 0.22 μm ﬁlter. The ﬁnal volume was standardized to 500 μL or 1 mL by adding
more methanol or methanol evaporation.
HPLC analyses were performed on an Agilent 1100 series HPLC system,
consisting of a quaternary pump (G1311A), a degasser (G1322A), a FLD detector
(G1321A) and a DAD detector (G1315B); column: Agilent ZORBAX SB-C18,
4.6 × 150 mm, 3.5 µm particle diameter size, 80 Å pore size. Analyses were
performed using a gradient of A: H2O containing 0.1% TFA (triﬂuoroacetic acid)
and B: MeCN (HPLC grade) containing 0.1% TFA with a ﬂow rate of 0.8 mL/min.
Gradient used: 0–5 min, 5% B; 5–9 min, 5–25% B; 9–29 min, 25–45% B; 29–40 min,
45–100% B; 40–45 min, 100% B; 45–50 min, 100–5% B; 50–55 min, 5% B. Injection
volume for all samples was 25 μL. Retention times (RTs) are denoted in minutes.
Absorption values at 210, 220, 256, and 575 nm were recorded. A full absorption
spectrum, from 230 to 700 nm, was recorded where peaks were observed in the
chromatogram. The quantiﬁcation methods of violacein are summarized
in Supplementary Methods. Chromatograms of commercial violacein and violacein
from cell extraction, and violacein calibration curve were generated after HPLC
analysis (Supplementary Fig. 14a–d).
Carotenoid extraction and LC-MS quantiﬁcation. The yeast strains were cultured
in 200 mL ﬂasks at 30 °C 220 r.p.m. for 48 h. The OD600 of all the yeast strains was
recorded and 10 mL of cell culture was collected by centrifugation at 15,000×g for
1 min and washed twice with deionized water. The cells were broken with glass
beads (1 g, 0.50–0.75 mm) by vortexing for 3 min, then 600 μL sorbitol (1 M) and
25 μL lyticase (25 mg/mL) were added. The mixture was vortexed for 10 min,
followed by 1 h incubation at 37 °C at 220 r.p.m. Pyrogallol of 1.25 mL 0.2%
(wt/vol) dissolved in methanol was added and mixed by vortexing for 10 s. KOH of
700 μL 60% (wt/vol) was added for saponiﬁcation and vortexed for 10 s, followed
by 1 h incubation at 75 °C with vortexing every 15 min. The carotenoid fraction
was extracted with 5–10 mL hexane, by mixing and left at room temperature
overnight with the instrument vertical mixing apparatus. The extraction mixture
was centrifuged at 3000×g for 5 min. The hexane layer was transferred to new
Eppendorf tubes and vacuum-dried for 30 min at 60 °C. The cell pellets were
repeated with hexane extraction. The vacuum-dried extractions were re-dissolved
in isopropanol and the whole metabolite was cleared with ultrasonication. The cell
debris was spun down and the supernatant was transferred to a new tube, followed
by lyophilization. The sample pellet was ﬁnally resuspended with 100 μL iso-
propanol and 2 μL of sample was injected into LC-MS equipment for chemical
analysis. Separation of lycopene and β-carotene and chemical analysis were per-
formed by the ACQUITY UPLC I-Class system (Waters) and the QTRAP 4500LC-
MS/MS system (SCIEX). The column for lycopene and β-carotene separation is
ACQUITY UPLC BEH C18 Column, 130 Å, 1.7 µm, 2.1 × 50 mm. Analyses were
performed using a gradient of A: 100% methanol and B: 50% methanol and 50%
isopropanol with a ﬂow rate of 0.3 mL/min. Gradient used: 0–0.5 min, 30% B;
0.5–1 min, 98% B; 1–4 min, 98% B; 4–4.1 min, 30% B; 4.1–5 min, 30% B. RTs are
denoted in minutes. The parameters for MS are as follows. λ source/gas parameters:
ion spay voltage: 5500; curtain gas: 35, nebulizer gas (gas 1) 55, ion source GS2 (gas
2) 55; interface heater temperature: 550. λ compound parameters: de-clustering
potential: 30; entrance potential: 10; collision cell exit potential: 10. The quantiﬁ-
cation methods of carotenoids are summarized in Supplementary Methods.
Chromatograms of commercial lycopene and β-carotene, and corresponding cali-
bration curves were generated after LC-MS analysis (Supplementary Fig. 14e–g).
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Next-generation sequencing and variation reconstruction. The genomic DNA
library was prepared for whole-genome sequencing according to the BGI’s standard
preparation protocol using the MGIEasy™ DNA Library Prep Kit V1. One
microgram of sample DNA was sheared using a Covaris LE220 to an average length
of 350 bp. After end-repairing and adapter ligation with barcode, it was PCR-
ampliﬁed and -puriﬁed. Subsequently, the PCR products with different barcodes
were pooled together at equimolar concentration. Sixty microliters of the pool was
heat-denatured, and mixed with an equal volume of circularization reaction buffer,
which contains 10 μL splint oligo, 12 μL splint buffer, 0.4 μL ligation enzyme, 1.2 μL
ligation enhancer, and 36.4 μL nuclease-free water. The mixture was subsequently
incubated at 37 °C for 60 min. Finally, 20 μL of each single-circle-library pool was
further used to prepare the DNA Nanoballs (DNB) and sequenced on the BGISEQ-
500 platform using BGISEQ-500 high-throughput sequencing kit (PE100).
Before mapping to genome, quality control of sequencing reads was performed.
Reads with length shorter than 100 bp or >1% of bases that have a Phred-based
quality lower than 10 or with unknown bases were removed. These cleaned reads
were mapped to synthetic yeast genome sequences using “Bowtie2” (version 2.0.0)
with standard parameters57. A similar approach to a previously published method
that combines both sequencing depth and split-read mapping was performed to
identify complex structural variation and SCRaMbLE events33. Reads that were
mapped to the reference were used to evaluate the sequencing depth by
“SAOPcoverage” (version 2.7.7). Reads that did not map to the reference were split
into pairwise ends with length of longer than 30 bp by scanning over all possible
intermediate positions. These pairwise ends were further aligned to the reference
using “Bowtie2”57. Combining the sequencing depth and split-read mapping, the
structural variations were reconstructed as described.
Data availability. All data and genetic material used for this paper are available
from the authors on request. The sequencing data of the SCRaMbLEd strains have
been deposited in the European Nucleotide Archive (ENA) under accession
PRJEB23542.
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